Amicus Therapeutics PE Ratio 2007-2021 | FOLD

Current and historical p/e ratio for Amicus Therapeutics (FOLD) from 2007 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Amicus Therapeutics PE ratio as of October 22, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Amicus Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 10.50 0.00
2021-06-30 9.64 $-0.96 0.00
2021-03-31 9.88 $-0.97 0.00
2020-12-31 23.09 $-1.07 0.00
2020-09-30 14.12 $-1.15 0.00
2020-06-30 15.08 $-1.14 0.00
2020-03-31 9.24 $-1.30 0.00
2019-12-31 9.74 $-1.51 0.00
2019-09-30 8.02 $-1.57 0.00
2019-06-30 12.48 $-2.17 0.00
2019-03-31 13.60 $-2.14 0.00
2018-12-31 9.58 $-1.86 0.00
2018-09-30 12.09 $-1.86 0.00
2018-06-30 15.62 $-1.71 0.00
2018-03-31 15.04 $-1.72 0.00
2017-12-31 14.39 $-1.83 0.00
2017-09-30 15.08 $-1.83 0.00
2017-06-30 10.07 $-1.47 0.00
2017-03-31 7.13 $-1.53 0.00
2016-12-31 4.97 $-1.49 0.00
2016-09-30 7.40 $-1.43 0.00
2016-06-30 5.46 $-1.42 0.00
2016-03-31 8.45 $-1.29 0.00
2015-12-31 9.70 $-1.19 0.00
2015-09-30 14.01 $-1.08 0.00
2015-06-30 14.15 $-0.98 0.00
2015-03-31 10.88 $-0.93 0.00
2014-12-31 8.32 $-0.93 0.00
2014-09-30 5.95 $-0.91 0.00
2014-06-30 3.34 $-0.98 0.00
2014-03-31 2.07 $-1.07 0.00
2013-12-31 2.35 $-1.17 0.00
2013-09-30 2.32 $-1.15 0.00
2013-06-30 2.33 $-1.20 0.00
2013-03-31 3.17 $-1.09 0.00
2012-12-31 2.68 $-1.09 0.00
2012-09-30 5.20 $-0.64 0.00
2012-06-30 5.50 $-0.58 0.00
2012-03-31 5.28 $-0.75 0.00
2011-12-31 3.44 $-0.79 0.00
2011-09-30 3.84 $-1.52 0.00
2011-06-30 5.94 $-1.80 0.00
2011-03-31 7.09 $-1.84 0.00
2010-12-31 4.70 $-1.99 0.00
2010-09-30 3.92 $-0.06 0.00
2010-06-30 2.24 $-0.09 0.00
2010-03-31 3.19 $-0.28 0.00
2009-12-31 3.97 $-0.29 0.00
2009-09-30 8.75 $-2.37 0.00
2009-06-30 11.45 $-2.14 0.00
2009-03-31 9.13 $-1.95 0.00
2008-12-31 7.98 $-1.74 0.00
2008-09-30 15.12 $-1.64 0.00
2008-06-30 10.68 $-1.74 0.00
2008-03-31 10.70 $-2.70 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.799B $0.261B
AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76